• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Athira Pharma Inc.

    2/27/25 4:30:28 PM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ATHA alert in real time by email
    S-8 1 atha_february_2025_s-8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 27, 2025

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S‑8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

    ATHIRA PHARMA, INC.

    (Exact name of Registrant as specified in its charter)

     

     

    Delaware

     

    45-3368487

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

     

     

    18706 North Creek Parkway, Suite 104

    Bothell, WA 98011

    (Address of principal executive offices, including zip code)

     

     

    2020 Equity Incentive Plan
    2020 Employee Stock Purchase Plan

     

    (Full title of the plans)

     

     

    Mark Litton, Ph.D.

    President and Chief Executive Officer

    Athira Pharma, Inc.

    18706 North Creek Parkway, Suite 104

    Bothell, WA 98011

    (425) 620-8501

    (Name, address and telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    Michael Nordtvedt

    Bryan D. King

    Wilson Sonsini Goodrich & Rosati,

    Professional Corporation

    701 Fifth Avenue, Suite 5100

    Seattle, WA 98104

    (206) 883-2500

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐

    Accelerated filer ☐

    Non-accelerated filer ☒

    Smaller reporting company ☒

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

     

     

     

     

     


    EXPLANATORY NOTE

    REGISTRATION OF ADDITIONAL SECURITIES

    PURSUANT TO GENERAL INSTRUCTION E

    This Registration Statement on Form S-8 (the “Registration Statement”) is filed by Athira Pharma, Inc. (the “Registrant”) for the purpose of registering (1) 1,952,047 shares of common stock of the Registrant reserved for issuance under the Athira Pharma, Inc. 2020 Equity Incentive Plan (the “2020 Plan”), pursuant to the provision of the 2020 Plan providing for such automatic increase in the number of shares reserved for issuance, and (2) 390,409 shares of common stock of the Registrant reserved for issuance under the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan (the “2020 ESPP”), pursuant to the provision of the 2020 ESPP providing for such automatic increase in the number of shares reserved for issuance. Accordingly, contents of the previous Registration Statements on Form S-8 filed by the Registrant with the Securities and Exchange Commission (the “Commission”), (1) September 18, 2020 (File No. 333-248910), (2) March 26, 2021 (File No. 333-254735), (3) March 28, 2022 (File No. 333-263907), (4) March 23, 2023 (File No. 333-270792), and (5) February 22, 2024 (File No. 333-277276) (together, the “Previous Forms S-8”), including the information incorporated by reference therein and the periodic reports filed after the Previous Forms S-8 to maintain current information about the Registrant, are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8.

    PART II

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the Commission:

    (1) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 27, 2025. pursuant to Section 13(a) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”);

    (2) All other reports filed with the Commission pursuant to Section 13(a) or 15(d) of the Exchange Act (other than the reports, or portions thereof, deemed to have been furnished and not filed with the Commission) since the end of the fiscal year covered by the Annual Report referred to in (1) above; and

    (3) The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-39503) filed with the Commission on September 9, 2020, pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


    Item 8. Exhibits.

     

    Exhibit

    Number

     

    Exhibit Description

     

    Form

     

     

    Incorporated by
    Reference

     

     

    Filing Date

     

     

     

     

     

     

     

     

    File No.

     

     

    Exhibit

     

     

     

     

     

     

     

     

     

     

    99.1

     

    Specimen common stock certificate of the Registrant

     

     

    S-1/A

     

     

     

    333-248428

     

     

     

    4.1

     

     

     

    September 14, 2020

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.2

     

    2020 Equity Incentive Plan

     

     

    S-1/A

     

     

     

    333-248428

     

     

     

    10.5

     

     

     

    September 8, 2020

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.3

     

    Form of Stock Option Agreement under the 2020 Equity Incentive Plan

     

     

    S-1/A

     

     

     

    333-248428

     

     

     

    10.6

     

     

     

    September 8, 2020

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.4

     

    Form of Restricted Stock Award Agreement under the 2020 Equity Incentive Plan

     

     

    S-1/A

     

     

     

    333-248428

     

     

     

    10.7

     

     

     

    September 8, 2020

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.5

     

    Form of RSU Agreement under the 2020 Equity Incentive Plan

     

     

    S-1/A

     

     

     

    333-248428

     

     

     

    10.8

     

     

     

    September 8, 2020

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.6

     

    2020 Employee Stock Purchase Plan, as amended and Form of Subscription Agreement thereunder

     

     

    10-K

     

     

     

    001-39503

     

     

     

    10.8

     

     

     

    March 23, 2023

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    5.1

     

    Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    23.1

     

    Consent of Independent Registered Public Accounting Firm

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    23.2

     

    Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (contained in Exhibit 5.1 hereto)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    24.1

     

    Power of Attorney (contained on signature page hereto)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    107

     

    Filing Fee Table

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bothell, State of Washington, on February 27, 2025.

     

    ATHIRA PHARMA, INC.

     

     

    By:

     

    /s/ Mark Litton

     

     

    Mark Litton, Ph.D.

     

     

    President and Chief Executive Officer

     


    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark Litton and Robert Renninger, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this registration statement, including post-effective amendments, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith and about the premises, as fully for all intents and purposes as they, he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or any of them, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

     

    Title

     

    Date

     

     

     

    /s/ Mark Litton

    Mark Litton

     

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

     

    February 27, 2025

     

     

     

    /s/ Robert Renninger

    Robert Renninger

     

    Senior Vice President, Finance and Accounting

    (Principal Accounting and Financial Officer)

     

    February 27, 2025

     

     

     

    /s/ Kelly A. Romano

    Kelly A. Romano

     

    Chair of the Board of Directors

     

    February 27, 2025

     

     

     

    /s/ Joseph Edelman

    Joseph Edelman

     

    Director

     

    February 27, 2025

     

     

     

    /s/ John M. Fluke, Jr.

    John M. Fluke, Jr.

     

    Director

     

    February 27, 2025

     

     

     

    /s/ James A. Johnson

    James A. Johnson

     

    Director

     

    February 27, 2025

     

     

     

     

     

    /s/ Barbara Kosacz

    Barbara Kosacz

     

    Director

     

    February 27, 2025

     

     

     

     

     

    /s/ Michael Panzara

    Michael Panzara

     

    Director

     

    February 27, 2025

     

     

     

     

     

    /s/ Grant Pickering

    Grant Pickering

     

    Director

     

    February 27, 2025

     


    Get the next $ATHA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATHA

    DatePrice TargetRatingAnalyst
    9/19/2024$5.00 → $0.50Outperform → Neutral
    Mizuho
    9/4/2024Buy → Neutral
    Rodman & Renshaw
    9/4/2024Buy → Neutral
    BTIG Research
    9/4/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/19/2024$22.00Buy
    Rodman & Renshaw
    10/17/2022$20.00Mkt Perform → Mkt Outperform
    JMP Securities
    7/7/2022$6.00Buy
    Mizuho
    6/23/2022$36.00 → $5.00Buy → Hold
    Stifel
    More analyst ratings

    $ATHA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF MEDICAL OFFICER San Martin Javier converted options into 4,667 shares and sold $11,311 worth of shares (1,644 units at $6.88), increasing direct ownership by 42% to 10,189 units (SEC Form 4)

    4 - Athira Pharma, Inc. (0001620463) (Issuer)

    1/5/26 7:52:35 PM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Litton Mark James sold $17,792 worth of shares (2,586 units at $6.88) and converted options into 10,834 shares, increasing direct ownership by 25% to 40,828 units (SEC Form 4)

    4 - Athira Pharma, Inc. (0001620463) (Issuer)

    1/5/26 7:51:49 PM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Renninger Robert was granted 1,000 shares, converted options into 1,236 shares and sold $2,043 worth of shares (297 units at $6.88), increasing direct ownership by 18% to 12,857 units (SEC Form 4)

    4 - Athira Pharma, Inc. (0001620463) (Issuer)

    1/5/26 7:50:54 PM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATHA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Athira Pharma downgraded by Mizuho with a new price target

    Mizuho downgraded Athira Pharma from Outperform to Neutral and set a new price target of $0.50 from $5.00 previously

    9/19/24 7:34:53 AM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Athira Pharma downgraded by Rodman & Renshaw

    Rodman & Renshaw downgraded Athira Pharma from Buy to Neutral

    9/4/24 8:27:09 AM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Athira Pharma downgraded by BTIG Research

    BTIG Research downgraded Athira Pharma from Buy to Neutral

    9/4/24 7:28:38 AM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATHA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker "LONA"

    BOTHELL, Wash., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it has changed its name to LeonaBio, Inc. The name change aligns with the Company's transformative acquisition of rights to develop and commercialize lasofoxifene, a promising late-stage clinical asset for the potential treatment of metastatic breast cancer, currently in a Phase 3 trial (NCT05696626). In connection with the name change, the Company will change its ticker symbol to "LONA." The Company's common stock will commence trading on The Nasdaq

    1/9/26 7:00:00 AM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

    Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing Co-Led by Commodore Capital, Perceptive Advisors and TCGX Supports Development of Lasofoxifene through Phase 3 Clinical Topline Data Readout and Regulatory Milestones Conference Call Today at 8:30 am Eastern Time BOTHELL, Wash., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, today announced that it has entered into an agreement to acquire the right

    12/18/25 7:02:46 AM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update

    Continuing to explore strategic alternatives focusing on maximizing stockholder value   Presented results from Phase 1 clinical trial of ATH-1105 in healthy volunteers demonstrating a favorable safety and tolerability profile as well as dose proportional pharmacokinetics and CNS penetration, supporting continued clinical development  BOTHELL, Wash., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended September 30, 2025, and provided recent business updates.  "We continue to explore

    11/6/25 4:05:00 PM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATHA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Athira Pharma Inc.

    SCHEDULE 13D/A - LeonaBio, Inc. (0001620463) (Subject)

    1/16/26 4:46:57 PM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Athira Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Leadership Update, Financial Statements and Exhibits

    8-K - LeonaBio, Inc. (0001620463) (Filer)

    1/9/26 4:05:29 PM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Athira Pharma Inc.

    SCHEDULE 13D/A - Athira Pharma, Inc. (0001620463) (Subject)

    12/23/25 5:16:56 PM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATHA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Romano Kelly A bought $100,051 worth of shares (42,400 units at $2.36), increasing direct ownership by 111% to 80,715 units (SEC Form 4)

    4 - Athira Pharma, Inc. (0001620463) (Issuer)

    6/25/24 7:21:55 PM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Perceptive Advisors Llc bought $1,462,895 worth of shares (605,686 units at $2.42) (SEC Form 4)

    4 - Athira Pharma, Inc. (0001620463) (Issuer)

    12/29/23 5:24:55 PM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATHA
    Leadership Updates

    Live Leadership Updates

    View All

    Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

    BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Javier San Martin, M.D., as Chief Medical Officer. Dr. San Martin brings more than 25 years of drug development experience and a proven track record leading cross-functional product teams to drive global development and commercialization strategies for multiple drugs across large and rare diseases with significant unmet medical need. "We are pleased to welcome Javier to the team and are confident his insights and guidance will be i

    4/15/24 7:00:00 AM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer

    BOTHELL, Wash., May 22, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Andrew Gengos as Chief Financial Officer and Chief Business Officer, effective immediately. Mr. Gengos replaces Glenna Mileson, who is retiring after serving as Athira's Chief Financial Officer for eight years. "On behalf of the entire Athira team, we thank Glenna for her many years of service, particularly for her stewardship during our transition to a publicly traded company, and wish her well in retirement," said Mark Litton, Ph.D

    5/22/23 7:00:00 AM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ric Kayne Publishes Investor Presentation Highlighting Urgent Need for Changes to Athira's Board of Directors

    New, Independent, Shareholder-Centric Directors are Needed to Ensure ATH-1017's Significant Potential is Realized and Reverse Destruction of Shareholder Value by Athira's Current Board Launches Campaign Website with Additional Information for Shareholders: www.SaveAthira.com Urges Athira Shareholders to VOTE their BLUE Proxy Card TODAY Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ:ATHA) ("Athira" or the "Company"), today released a detailed presentation to Athira's shareholders demonstrating the need for immediate change on the Company's Board of Directors (the "Board"

    4/25/22 8:00:00 AM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATHA
    Financials

    Live finance-specific insights

    View All

    Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

    Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing Co-Led by Commodore Capital, Perceptive Advisors and TCGX Supports Development of Lasofoxifene through Phase 3 Clinical Topline Data Readout and Regulatory Milestones Conference Call Today at 8:30 am Eastern Time BOTHELL, Wash., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, today announced that it has entered into an agreement to acquire the right

    12/18/25 7:02:46 AM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update

    On track to report topline data from ACT-AD Phase 2 Alzheimer's disease study in 2Q22 Expect to complete enrollment in LIFT-AD Phase 3 Alzheimer's disease study in 3Q22 Conference call today at 4:30 pm Eastern time BOTHELL, Wash., March 24, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company's financial results for the year ended December 31, 2021 and provided a clinical update. "We entered 2022 with strong momentum from the solid foundation established throughout 2021 and have made considerable progress across

    3/24/22 4:05:00 PM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Athira Pharma to Host Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call on March 24, 2022

    BOTHELL, Wash., March 17, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced it will report financial results for the fourth quarter and full year ended December 31, 2021 and provide a business update on Thursday, March 24, 2022 following the close of the U.S. financial markets. Athira will host a conference call to discuss these results on Thursday, March 24, 2022 at 4:30 pm Eastern time (1:30 pm Pacific time). In order to participate in the conference call, please dial 833-614-1520 (domestic) or 516-575-8710 (internationa

    3/17/22 7:00:00 AM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATHA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Athira Pharma Inc.

    SC 13G/A - Athira Pharma, Inc. (0001620463) (Subject)

    11/14/24 4:17:23 PM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Athira Pharma Inc.

    SC 13G - Athira Pharma, Inc. (0001620463) (Subject)

    11/7/24 1:15:00 PM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Athira Pharma Inc.

    SC 13D/A - Athira Pharma, Inc. (0001620463) (Subject)

    10/31/24 4:16:28 PM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATHA
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Breaking: Stock Acquired at Athira Pharma Inc. on Jun 25

    Recently, on June 25, 2024, Director Romano Kelly A bought $100,051 worth of shares in Athira Pharma Inc. This transaction involved acquiring 42,400 units at $2.36 per share, resulting in a significant increase in direct ownership by 111% to 80,715 units. The purchase was disclosed in the SEC Form 4 filing. Insider buying is often considered a bullish signal as insiders may have insights into the company's future performance. It's essential to analyze this insider purchase in conjunction with previous insider transactions to identify any patterns or trends. Taking into account the information from the SEC filings, several other insiders at Athira Pharma Inc. have also been active in the sto

    6/26/24 3:07:15 PM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care